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Brain metastases are common in many types of cancer. Treatment for this condition
is usually through surgical resection, whole brain radiation treatment (WBRT),
stereotactic radiosurgery (SRS), or stereotactic radiation therapy (SRT). SRS (15 to
24 Gy in 1 fraction) and SRT (21, 24 or 30 Gy in 3 fractions or 25, 30 Gy in 5
fractions) have similar biological equivalent doses but differ in the number of
treatments the radiation is delivered over. The objective of this study is to use
national cancer database (NCDB) to examine the factors associated with receiving
SRS as compared to SRT, and to compare overall survival between patients who
received SRS to those who received SRT after adjusting for all potential prognostic
factors.
Descriptive statistics for categorical and continuous variables are reported.
Predictors of SRS use as compared to SRT were identified using the logistic
regression model. The OR was reported as the measure of association with
likelihood of using SRS. Survival time was measured in months from the date of
diagnosis to the date of death. We used the Kaplan-Meier (KM) method to
generate survival curves and analyzed the differences between groups using the
log-rank test. Cox proportional hazards regression analysis was conducted to
estimate the hazard ratio (HR). We used SAS 9.4 (SAS Institute Inc.) for the
analysis.
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OBJECTIVES
Variables Multivariable Analysis P-value
HR (95% CI)
Age 1.015 (1.012-1.018) 0.001
Sex Male Ref
Female 0.819 (0.775-0.865) 0.001
Race
White Ref
Black 0.907 (0.829-0.992) 0.03
Other 0.750 (0.645-0.872) 0.002
Income >=$35,000 Ref








1 1.136 (1.066-1.211) 0.001




No 1.681 (1.578-1.791) 0.001
Primary 
Cancer
Breast 0.647 (0.513-0.816) 0.002
NSCLC 0.790 (0.689-0.906) 0.008
SCLC 0.970 (0.794-1.185) 0.76
Other Lung 0.977 (0.802-1.189) 0.81
Melanoma 0.501 (0.418-0.600) 0.001




2010-2013 1.075 (1.017-1.137) 0.010
2014-2015 Ref
Variables Multivariable Analysis P-value
OR (95% CI)
Charlson/Deyo Score 0 Ref
1 0.836 (0.728-0.961) 0.011
>=2 0.780 (0.647-0.940) 0.009
Chemotherapy Yes Ref
No 0.823 (0.722-0.938) 0.003
Primary Cancer Breast 0.703 (0.438-1.129) 0.15
NSCLC 0.898 (0.648-1.245) 0.52
SCLC 0.951 (0.592-1.528) 0.84
Other Lung 0.628 (0.407-0.972) 0.04
Melanoma 0.650 (0.443-0.955) 0.03
CRC 0.499 (0.270-0.922) 0.03
Renal Cell Ref
Year of Diagnosis 2010-2013 1.357 (1.208-1.523) 0.001
2014-2015 Ref
Figure 1: In this figure, the 0 represents SRT data, and the 1 represents SRS data. The median survival 
for patients undergoing SRS treatment is 10.91 months, and the median survival for patients undergoing 
SRT treatment is 11.30 months. No significant difference in overall survival between these two groups.
Table 1 Multivariable logistic regression analysis of factors associated with receipt of SRS as compared to 
SRT. Other variables that were included but not found to hold significance are as follows: age, sex, race, 
education, income, place of living, hospital type, insurance status.
Table 2 Multivariable Cox proportional hazards regression analysis of factors associated with overall 
survival. Other variables that were included but not found to have a significant effect include treatment 
combination, education, and place of living.
INTRODUCTION
METHODS
Brain metastases (BM) are a result of advanced stage cancer that pose a threat to
the life of an individual. This can be treated using surgical resection with aims to
help improve neurological functioning and mass reduction (1). Other treatments
possible include whole brain radiation treatment (WBRT), stereotactic radiosurgery
(SRS), stereotactic radiation therapy (SRT), systemic steroids, as well as
combinations of these treatments (2). WBRT has been the traditional approach to
treating BM; however, targeted treatments such as SRT can be more beneficial
clinically, as well as present less risk for radiation toxicity (2). This is because SRT
can provide high doses of radiation in a small number of fractions to a specific
area (3). Comparatively, SRS utilizes a single fraction of high dose radiation to an
area (4), but does come with some radiation toxicity concerns itself (3). SRT
attempts to branch this gap by continuing to deliver high doses of radiation, but
spread out over several fractions to help reduce the radiation being delivered in a
single treatment period. SRT could even help in specific areas of the brain. A study
found that some areas of the brain may exhibit the different levels of sensitivity to
radiation. The visual pathway has been found to be more sensitive to radiation,
meaning risk for damage as a result of treatment is higher around this cranial
nerve (6). With these options of treatments and concerns, it is important to look
into the data in recent years to see the factors leading to receiving SRT treatment
as compared to SRS treatment. Observing how these variables, including
treatment type, affect the overall survival of patients diagnosed with BM is also
critical.
CONCLUSIONS
In conclusion, SRT and SRS were not found to have a significant difference in
survival. Further study is warranted to determine if SRT is less toxic than SRS.
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